

Ref. No.: ADL/SE/2020-21

July 16, 2020

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai 400 001

To,
Listing/ Compliance Department
**National Stock Exchange of India
Limited**
“Exchange Plaza”, Plot No C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

BSE CODE: 524348

NSE CODE: AARTIDRUGS

Sir/ Madam,

**Sub:- Revised Disclosure of Impact of COVID-19 Pandemic
Ref: SEBI Circular No.SEBI/HO/CFD/CMD1/CIR/P/2020/84
dated May 20, 2020**

With reference to discrepancy mail received from NSE dated July 8, 2020 and in line with above mentioned SEBI circular we are submitting herewith revised disclosure with reference to the impact of COVID-19 pandemic on various aspects of the business activities of the Company as below;

Manufacturing Activities: Healthcare Industry being into essential services has not been adversely impacted of countrywide lockdown. The operations at our manufacturing facilities continued except for the period March 24-29, 2020 wherein majority of the employees could not reach to factory location because of restriction on the movement of manpower, unavailability of transportation etc. Subsequently, based on our product profile, we were granted permissions to operate our manufacturing facilities, movement of critical workforce, materials, etc.

Steps taken for Smooth Functioning of Operations and Future Impact: We took various initiatives such as social distancing, thermal screening, availability of face masks and sanitizers, awareness campaigns, fumigation, arrangement of Company buses for transportation of staff, sanitation at factories for the safety and security of our staff which helped to improve the morale of employees and resulted in smoothening the manufacturing functions. Due to scarcity of logistics facility supply of raw material and dispatches of finished goods were affected at initial stage of lockdown which has now improved and clocked close to normalcies. From the time of commencement of lockdown, Company has provided the Work from Home facility to employees of Mumbai Head office with necessary connectivity. All IT Security Protocols are in place and all systems are being monitored remotely. On the basis of this scenario and to the best of our information and knowledge, there may not be any material impact on the operations of the Company in future due to COVID-19.

Capital and Financial Resources: There is likely to be no impact on the capital and financial resources, profitability and liquidity position of the Company. The

smooth movement of cash flows will ensure ability to service debt and other financing arrangements. The Company does not foresee any challenge in realizing/recovering its assets. There was no adverse impact on internal financial reporting and control. The Company has however implemented stringent control measures across the organization to address any evolving situation resulting from the pandemic.

Supply Chain and Customer Demand and Contracts: Supply chain is almost normal except some impact on the transportation cost, which the Company has been passing on to the customer.

Due to essential nature of Company's business and pharmaceuticals being included in essential goods we don't see any impact on demand of products.

The Company is well positioned to fulfil its obligations and existing contracts/arrangements. At present, we do not foresee any contract/agreements which will have an adverse impact on the business in case of non-fulfilment of obligations by any party.

This update is dynamic and will change as the situation changes, which is not in the control of the Company. In event of any change takes place, the Company will continue to provide an update on the situation.

You are requested to take the same on records.

Thanking you,

Yours Faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. NO. A54527